Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy ITGR?
Source: Businesswire
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 87.210
Low
75.00
Averages
86.25
High
95.00
Current: 87.210
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artisan Small Cap Fund Q4 2025 Investor Letter Highlights
- Portfolio Performance: Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, demonstrating its ability to achieve positive results amid market volatility despite trailing for the full year.
- Exit from Integer Holdings: The fund exited its investment in Integer Holdings Corporation during Q4 due to unmet earnings growth expectations, revenue slowdown, and lack of margin improvement, compounded by a leadership transition that raised concerns about future profit cycles.
- Hedge Fund Holdings Shift: By the end of Q4 2025, 32 hedge funds held Integer Holdings, up from 24 in the previous quarter, indicating increased market interest, yet the fund believes that other AI stocks present greater upside potential.
- Market Environment Impact: The market in 2025 experienced frequent sentiment shifts influenced by U.S. politics, trade policy, and geopolitical tensions, yet the fund remains focused on identifying profit cycles at reasonable valuations to navigate future market challenges.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
Artisan Small Cap Fund Q4 2025 Investor Letter Highlights
- Portfolio Performance: Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, demonstrating its ability to achieve positive results amid market volatility despite trailing for the full year.
- Exit from Integer Holdings: The fund exited its investment in Integer Holdings Corporation during Q4 due to unmet earnings growth expectations, revenue slowdown, and lack of margin improvement, compounded by a leadership transition that raised concerns about future profit cycles.
- Hedge Fund Holdings Shift: By the end of Q4 2025, 32 hedge funds held Integer Holdings, up from 24 in the previous quarter, indicating increased market interest, yet the fund believes that other AI stocks present greater upside potential.
- Market Environment Impact: The market in 2025 experienced frequent sentiment shifts influenced by U.S. politics, trade policy, and geopolitical tensions, yet the fund remains focused on identifying profit cycles at reasonable valuations to navigate future market challenges.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
